COMMUNIQUÉS West-GlobeNewswire

Calidi Biotherapeutics Announces Proposed Public Offering
13/11/2024
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
13/11/2024
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Jasper Therapeutics to Participate at Upcoming Investor Conferences
13/11/2024
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
13/11/2024
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - - Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for [...]
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
13/11/2024
MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2024 on [...]
Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis
13/11/2024
– Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH – – Kriya plans to evaluate KRIYA-497, a one-time intramuscular gene therapy [...]
Natural Alternatives International, Inc. Announces 2025 Q1 Results
13/11/2024
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today [...]
Telix ADSs Commence Trading on Nasdaq
13/11/2024
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq [...]
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data, [...]
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML [...]
Voting Rights and Shares Capital of the Company
13/11/2024
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 13, 2024 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
13/11/2024
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 nov. 2024 (GLOBE NEWSWIRE) -- Paris, France, le 13 novembre 2024 Place de cotation [...]
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
13/11/2024
TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based [...]
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
13/11/2024
PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024 Launch of Iqirvo® (elafibranor) 1 on track with expectations; encouraging feedback from healthcare providers and [...]
GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024
13/11/2024
Programme PBC (sous licence Ipsen) : Ipsen présentera de nouvelles données sur elafibranor à l’AASLD Liver Meeting® 2024 Lancement commercial d’Iqirvo® (elafibranor) 1 conforme aux attentes ; retours encourageants des [...]
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
13/11/2024
Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development [...]
Integra’s DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research
13/11/2024
The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of [...]
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
13/11/2024
– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
13/11/2024
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]

Pages